HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Goro Matsumiya Yoshiki Sawa Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fukui, S. Articles by Sawa, Y. Search for Related Content PubMed PubMed Citation Articles by Fukui, S. Articles by Sawa, Y. Related Collections Myocardial infarction

---

Original Articles: Cardiovascular

Therapeutic Effect of Midkine on Cardiac Remodeling in Infarcted Rat Hearts

^a Division of Cardiovascular Surgery, Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
^b Molecular Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan
^c Foundation for Biomedical Research and Innovation, Kobe, Japan
^d Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan

Accepted for publication June 1, 2007.

^_* Address correspondence to Dr Sawa, Division of Cardiovascular Surgery, Department of Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Osaka, 565-0871, Japan (Email: yshksw{at}hotmail.com).

Background: Midkine is expressed in the developing fetus and in adult organs stressed by ischemia, but its physiologic role in ischemic organs is poorly understood. Here we investigated the effect of midkine on cardiac remodeling after ischemia caused by myocardial infarction.

Methods: The expression pattern of the endogenous midkine gene in rat heart was evaluated by real-time polymerase chain reaction for 2 weeks after myocardial infarction. To investigate its effect, recombinant midkine was injected into hearts 2 weeks after myocardial infarction, and cardiac functions were monitored by echocardiography. Six weeks later, the hearts were removed, and the areas of infarcted and viable tissue and the extent of cardiomyocyte hypertrophy were determined histologically.

Results: The midkine gene was strongly upregulated in the infarcted myocardium, but this upregulation lasted less than 2 weeks. Cardiac remodeling was significantly and dose-dependently attenuated by midkine treatment. The midkine treatment also increased collagen accumulation and facilitated angiogenesis in the infarcted area, and the viable muscle area after myocardial infarction dose-dependently increased. Despite this increase of viable muscle area, the midkine-treated hearts showed significantly less cardiomyocyte hypertrophy than vehicle-treated hearts, suggesting midkine had prevented chronically ischemic cells from dying and dropping out by angiogenesis.

Conclusions: Our results indicate midkine can attenuate cardiac remodeling after myocardial infarction, and suggest midkine has therapeutic potential for subacute myocardial infarction.

This article has been cited by other articles:

				H. Takenaka, M. Horiba, H. Ishiguro, A. Sumida, M. Hojo, A. Usui, T. Akita, S. Sakuma, Y. Ueda, I. Kodama, et al. Midkine prevents ventricular remodeling and improves long-term survival after myocardial infarction Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H462 - H469. [Abstract] [Full Text] [PDF]